Q4 2024 Earnings Call Transcript February 11, 2025 Royalty Pharma plc misses on earnings expectations. Reported EPS is ...

Rexel posted further growth in digitalization, with digital now representing 32% of sales in Q4 2024, up +232bps compared to Q4 2023. Europe was at 43% of digital sales, up +357bps, North America was ...

Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell ...

In the fourth quarter of 2024, the Income tax provision was $125.7 million on income before income taxes of $483.3 million.

Q3 2025 Earnings Conference Call February 12, 2025 2:30 AM ETCompany ParticipantsYoshimitsu Goto - Board Director ...

Q2 2025 Results Conference Call February 10, 2025 5:00 PM ETCompany ParticipantsMatt Gunter - Investor RelationsTim Danker ...

Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell engagers, with $52.0 million in upfront payments Extended ant ...

FOURTH QUARTER Total revenue, including billable expenses, was $2.9 billion Revenue before billable expenses ("net revenue") was $2.4 billion, with ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.3cY8rBmp.js ...

Heineken Holding N.V. reports 2024 full year resultsAmsterdam, 12 February 2025 – Heineken Holding N.V. [(EURONEXT: HEIO; OTCQX: HKHHY)] ...

On December 12, 2024, the Company reported that its Board of Directors increased its quarterly cash dividend to $0.880 per share, equivalent to an annualized dividend rate of $3.52 per share. The ...

While our fiscal 2025 projections see the firm remain slightly above this target at 3.3 turns, we expect Starbucks ot return to 3.0 times leverage by 2026 and remain below that benchmark throughout ...